Zhongtong Finance APP learned that on June 24th, Zhuyun Health (09955) announced a major business breakthrough, successfully obtaining exclusive sub-licensing authorization for injection of iloprost solution, and will be fully responsible for the commercial operation of the product in the Greater China region (including mainland China, Hong Kong, and Macau). Relying on the advantages of the hospital SaaS system and pharmacy SaaS system platforms and professional digital promotion capabilities, Zhuyun Health will strive to improve medication accessibility and benefit more than one million pulmonary artery hypertension patients in China.

Pulmonary arterial hypertension refers to a clinical and pathophysiological syndrome caused by changes in the structure or function of pulmonary blood vessels and an increase in pulmonary vascular resistance and pulmonary artery pressure caused by various heterogeneous diseases and different pathogenesis. It is estimated that about 1% of the world's population is affected by this disease, and the number of pulmonary arterial hypertension patients in China exceeds 5 million, including 1.3-2.07 million NYHA III-IV patients, which seriously affects the quality of life and life expectancy of patients and urgently needs effective treatment measures to improve the condition.

As a field with a large number of patients and unsatisfied treatment, the global pulmonary arterial hypertension treatment market is expected to reach US$11 billion by 2030, attracting many global pharmaceutical giants to enter the market, such as Merck's US$11.5 billion acquisition of Acceleron in 2021 to obtain treatment of pulmonary arterial hypertension drug WinrevairTM (sotatercept), this drug has been approved by the FDA for marketing in March of this year. In recent years, China has also maintained relatively rapid market growth in the field of pulmonary arterial hypertension. After the publication of the 2021 pulmonary arterial hypertension treatment guidelines, the awareness, diagnosis and treatment rates continue to increase, and it is expected that the compound growth rate of the market in the next 3-5 years will remain above 30%.

Faced with such a large patient group and huge market potential, Zhuyun Health keenly recognized the unsatisfied clinical needs and exclusively introduced iloprost injection as a high-risk treatment drug for pulmonary arterial hypertension. As the only generic drug in the world, there is no similar injection product with the same content on the domestic market, and this product will effectively fill the gaps in the domestic market.

It is reported that the registration classification of injection iloprost solution belongs to Class 5.2 and can be attributed to the medication for rare diseases (IPAH), and has the opportunity to enjoy the "priority review and approval process", with a short market entry cycle and is expected to benefit patients as soon as possible. In addition to pulmonary arterial hypertension, the indications for injection of iloprost solution are expected to continue to extend to other fields such as thrombotic occlusive arteritis (TAO), Raynaud's phenomenon (RP) and PAOD, opening up more growth space for product layout in the field of cardiovascular disease treatment.

As a leading domestic digital health management platform, Zhuyun Health has long been committed to providing more convenient and efficient medical products and services for patients through technological innovation and resource integration. The exclusive sub-licensing authorization for injection of iloprost solution obtained this time is an important measure for Zhuyun Health to lay out the pulmonary arterial hypertension market worth tens of billions of dollars, marking that Zhuyun Health has taken a solid step in realizing the 'from patient to industry' (P2M) strategy, and is expected to continue to enhance the company's profitability and differentiation advantages.

In the future, Zhuyun Health will actively explore innovative business models on the basis of consolidating existing advantageous business foundations, continuously carry out forward-looking layouts oriented to clinical needs of patients, and strive to popularize more high-quality products and services for the majority of patients. At the same time, Zhuyun Health will also work with various partners to jointly promote the development of the domestic medical industry and create more health benefits for the vast number of patients.